
~~WHAT IS~~ CLAIM~~ED IS~~

1. A pharmaceutical composition for topical administration to a mammal comprising two or more pharmaceutically acceptable excipients and a therapeutically effective amount of a spiro-oxindole compound having the following formula:



;

or a pharmaceutically acceptable salt thereof, wherein the pharmaceutically acceptable excipients are selected from:

(a) one or more solvents selected from PEG 400 at concentration of from 30% w/w to 70% w/w and PEG 3350 at a concentration of from 10% w/w to 50% w/w;

(b) one or more penetration enhancing agents selected from diethylene glycol monoethyl ether at a concentration of from 2% w/w to 25% w/w, oleyl alcohol at a concentration of from 1% w/w to 10% w/w and isopropyl myristate at a concentration of from 1% w/w to 25% w/w;

(c) one or more stiffening agents selected from stearyl alcohol at a concentration of from 0.1% w/w to 10% w/w; and

(d) an ointment base selected from PEG 400 at concentration of from 30% w/w to 70% w/w and PEG 3350 at a concentration of from 10% w/w to 50% w/w.

~~2. The pharmaceutical composition of Claim 1, wherein the pharmaceutically acceptable excipients are selected from one or more solvents, one or more penetration enhancing agents, one or more stiffening agents, or one or more ointment bases.~~

~~3~~2. The pharmaceutical composition of Claim ~~2~~1, further comprising one or more antioxidants.

~~4~~3. The pharmaceutical composition of Claim 2 ~~or 3~~, wherein ~~each pharmaceutically acceptable excipient is present in a concentration of from about 0.01% w/w to about 99% w/w~~an antioxidant is butylated hydroxytoluene (BHT) at a concentration of from

0.01% w/w to 2% w/w.

~~5. The pharmaceutical composition of Claim 4, wherein a solvent is selected from PEG 400 or PEG 3350, a penetration enhancing agent is selected from diethylene glycol mono ether, oleyl alcohol, or isopropyl myristate, a stiffening agent is stearyl alcohol, an ointment base is selected from PEG 400 or PEG 3350, and the antioxidant is butylated hydroxytoluene (BHT).~~

~~6. The pharmaceutical composition of Claim 5, wherein PEG 400 is present in a concentration of from about 30% w/w to about 70% w/w, diethylene glycol mono ether is present in a concentration of from about 2% w/w to about 25% w/w, oleyl alcohol is present in a concentration of from about 1% w/w to about 10% w/w, isopropyl myristate is present in a concentration of from about 1% w/w to about 25% w/w, stearyl alcohol is present in a concentration of from about 0.1% w/w to about 10% w/w, BHT is present in a concentration of from about 0.01% w/w to about 2% w/w, and PEG 3350 is present in a concentration of from about 10% w/w to about 50% w/w.~~

~~7~~4. The pharmaceutical composition of Claim ~~6~~3, wherein PEG 400 is present in a concentration of from ~~about~~ 45% w/w to ~~about~~ 55% w/w, diethylene glycol mono ether is present in a concentration of from ~~about~~ 5% w/w to ~~about~~ 15% w/w, oleyl alcohol is present in a concentration of from ~~about~~ 2.5% w/w to ~~about~~ 7.5% w/w, isopropyl myristate is present in a concentration of from ~~about~~ 2.5% w/w to ~~about~~ 7.5% w/w, stearyl alcohol is present in a concentration of from ~~about~~ 0.1% w/w to ~~about~~ 7.5% w/w, BHT is present in a concentration of from ~~about~~ 0.05% w/w to ~~about~~ 1% w/w, and PEG 3350 is present in a concentration of from ~~about~~ 15% w/w to ~~about~~ 30% w/w.

~~8. The pharmaceutical composition of Claim 7, wherein the spiro-oxindole compound is present in a concentration of from about 0.1% w/w to about 10% w/w.~~

~~9~~5. The pharmaceutical composition of Claim ~~8~~4, wherein the spiro-oxindole compound is present in a concentration of from ~~about~~ 2% w/w to ~~about~~ 8% w/w.

~~10~~6. The pharmaceutical composition of Claim ~~1~~5 comprising the spiro-oxindole compound at a concentration of 2.0% w/w; PEG 400 at a concentration of 52.9% w/w;

diethylene glycol mono ether at a concentration of 10% w/w; oleyl alcohol at a concentration of 5% w/w; isopropyl myristate at a concentration of 5% w/w; stearyl alcohol at a concentration of 5% w/w; butylated hydroxytoluene at a concentration of 0.1% w/w; and PEG 3350 at a concentration of 20% w/w.

~~11~~7. The pharmaceutical composition of Claim ~~1~~ 5 comprising the spiro-oxindole compound at a concentration of 4% w/w; PEG 400 at a concentration of 50.9% w/w; diethylene glycol mono ether at a concentration of 10% w/w; oleyl alcohol at a concentration of 5% w/w; isopropyl myristate at a concentration of 5% w/w; stearyl alcohol at a concentration of 5% w/w; butylated hydroxytoluene at a concentration of 0.1% w/w; and PEG 3350 at a concentration of 20% w/w.

~~12~~8. The pharmaceutical composition of Claim ~~1~~ 5 comprising the spiro-oxindole compound at a concentration of 4% w/w; PEG 400 at a concentration of 50.9% w/w; diethylene glycol mono ether P at a concentration of 5% w/w; oleyl alcohol at a concentration of 5% w/w; isopropyl myristate at a concentration of 5% w/w; stearyl alcohol at a concentration of 10% w/w; butylated hydroxytoluene at a concentration of 0.1% w/w; and PEG 3350 at a concentration of 20% w/w.

~~13~~9. The pharmaceutical composition of Claim ~~1~~ 5 comprising the spiro-oxindole compound at a concentration of 8% w/w; PEG 400 at a concentration of 46.9% w/w; diethylene glycol mono ether P at a concentration of 10% w/w; oleyl alcohol at a concentration of 5% w/w; isopropyl myristate at a concentration of 5% w/w; stearyl alcohol at a concentration of 5% w/w; butylated hydroxytoluene at a concentration of 0.1% w/w; and PEG 3350 at a concentration of 20% w/w of the pharmaceutical composition.

~~14~~10. Use of a pharmaceutical composition of any one of Claims 1 to ~~13~~ 9 for the preparation of a medicament for topical administration to a mammal in need thereof, wherein the medicament is for treating~~, preventing~~ or ameliorating a sodium channel-mediated disease or a condition in the mammal.

~~15~~11. The use of Claim ~~14~~10, wherein said disease or condition is selected from the group consisting of neuropathic pain, inflammatory pain, visceral pain, post-herpetic neuralgia, cancer pain, chemotherapy pain, trauma pain, surgical pain, post-operative pain, pruritis,

osteoarthritis, trigeminal neuralgia, familial erythromelalgia, primary erythromelalgia, familial rectal pain, childbirth pain, labor pain, neurogenic bladder, ulcerative colitis, chronic pain, persistent pain, peripherally mediated pain, centrally mediated pain, chronic headache, migraine headache, sinus headache, tension headache, phantom limb pain, peripheral nerve injury, and combinations thereof.

~~16~~12. The use of Claim ~~14~~10, wherein the mammal is a human.

~~17~~13. Use of a pharmaceutical composition of any one of Claims 1 to ~~13~~ 9 for the preparation of a medicament for topical administration to a mammal in need thereof, wherein the medicament is for treating pain through inhibition of ion flux through a voltage-dependent sodium channel in the mammal.

~~18~~14. The use of Claim ~~17~~13, wherein the mammal is a human.